|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of ERK activation by hepatocyte growth factor (HGF) on eight HCC cell lines were further examined.
|
31702093 |
2020 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, UBE2Z knockdown could effectively reduce the expression of p-ERK, p-p38, p-JNK, p-Stat3 and p-JAK2, suggesting that UBE2Z might promote HCC progression by targeting ERK and stat3 signaling pathway.
|
31831168 |
2020 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KCNN4 promotes invasion and metastasis through the MAPK/ERK pathway in hepatocellular carcinoma.
|
31431469 |
2020 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More importantly, the effects of koumine upon mitochondria membrane potential, ROS production, and the phosphorylation of ERK, p38, p65, and IκBα could be significantly reversed by ROS inhibitor, indicating that koumine affects HCC cell fate and ERK/p38 MAPK and NF-κB signaling activity through producing excess ROS.
|
31581704 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the RAS-RAF-ERK-pathway using sorafenib as a first-line and regorafenib as a second-line treatment approach is the only effective therapeutic strategy for advanced hepatocellular carcinoma (HCC).
|
30685691 |
2019 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Mechanistically, silencing of IL13RA2 promotes partial epithelial-mesenchymal transition via increasing ERK phosphorylation in HCC.
|
31823484 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here we report that the down-regulation of YTHDF2 was specifically induced by hypoxia in hepatocellular carcinoma (HCC) cells, and that overexpression of YTHDF2 suppressed cell proliferation, tumor growth and activation of MEK and ERK in HCC cells.
|
30423408 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TF could promote the growth of HCC <i>in vitro</i> and <i>in vivo</i> by activating both ERK and AKT signaling pathways.
|
30931258 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, our findings suggest a regulatory network of ERK and AKT signaling through lncIHS, which is downstream of HBx-SMYD3, and they indicate that lncIHS may be a potential target for treating HCC.
|
31128422 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This altered PRMT6-ERK-PKM2 signaling axis was further confirmed in both a HCC mouse model with endogenous knockout of PRMT6 as well as in HCC clinical samples.
|
31469916 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conclusively, these findings indicate that mTOR and ERK play crucial roles in controlling VKORC1 expression in both hepatoma and hepatocytes, which provides a valuable molecular basis for preventing hemorrhage in clinical therapies.
|
30306378 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we have identified a novel KPNA3-AKT-ERK-TWIST signaling cascade that promotes EMT and mediates sorafenib resistance in HCC.
|
31417635 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
β-Thujaplicin induces autophagic cell death, apoptosis, and cell cycle arrest through ROS-mediated Akt and p38/ERK MAPK signaling in human hepatocellular carcinoma.
|
30874538 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PABA/NO induced apoptosis through inhibition of PI3K/Akt/mTOR and MEK/ERK pathway in hepatocellular carcinoma cells.
|
31555866 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased numbers of baseline flt-3+p-ERK+ MDSCs were associated with survival benefit of patients.CONCLUSIONA high baseline CD4+ T effector/Treg ratio is a potential biomarker of prognostic significance in HCC.
|
31391334 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results show that RhoC/ROCK2 may have a major effect on VM in HCC via ERK/MMPs signaling and might be a potential therapeutic target for the treatment of HCC.
|
30779947 |
2019 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined that PAA covalently binds to the conserved cysteine site of peroxiredoxins I/II (Prxs-I/II) and inhibits their catalytic activity, subsequently activating the ROS/ERK axis and the immunogenicity of HCC toward NK cells.
|
31130519 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results suggest that capsaicin-increased phosphorylation of ERK contributes to the enhanced antitumor activity of sorafenib, and capsaicin may be useful in improving the efficacy of sorafenib for the treatment of HCC.
|
29188798 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Monocytes/Macrophages promote vascular CXCR4 expression via the ERK pathway in hepatocellular carcinoma.
|
29399411 |
2018 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
We previously demonstrated that ERK-induced phosphorylation of XPO5 followed by peptidyl-prolyl cis/trans isomerase Pin1-mediated isomerization downregulates miRNA expression and contributes to hepatocellular carcinoma (HCC) development.
|
29445125 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, miR-3662 suppressed cell growth in vitro and in vivo, and induced G1/S cell cycle arrest. miR-3662 inhibited the activation of ERK and JNK signaling pathways in HCC.
|
29748591 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum from Chronic Hepatitis B Patients Promotes Growth and Proliferation via the IGF-II/IGF-IR/MEK/ERK Signaling Pathway in Hepatocellular Carcinoma Cells.
|
29763915 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mitochondrial fission promotes cell migration by Ca<sup>2+</sup> /CaMKII/ERK/FAK pathway in hepatocellular carcinoma.
|
29210177 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the inhibition of c-Met expression with a specific siRNA significantly inhibited cells growth and deregulated the ERK pathway in HCC.
|
30108016 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway.
|
29954442 |
2018 |